


Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH



March 1, 1998
Volume 58 • Number 5
PP. 859-1085
ISSN 0008-5472 • CNREA 8



International Aspirin® Award 1998

Young Researchers' Aspirin® Award

The Young Researchers' Aspirin® Award's objective is to encourage scientific research into the mechanism of action and clinical use of acetylsalicylic acid, the active ingredient of Aspirin®. Scientists who have contributed to the knowledge of Aspirin® through original independent scientific research in the field of theoretical (experimental) and/or clinical medicine are invited to compete for the Award. The results of their work should have a direct effect on the knowledge or use of Aspirin® and be based on a peer-reviewed publication, accepted and/or published. The publication should not be older than two years. Only 1 paper can be submitted per year but it might be resubmitted within the time limit. The age limit of the Young Researchers' Aspirin® Award in the year of candidature is 40.

The Young Researchers' Aspirin® Award's value is DM 20,000.

Entries will be judged by an international scientific committee representing basic and clinical research.

Submit your manuscript (English language, 2 copies) with your Curriculum Vitae, a list of the 5 most important recent publications (= last 5 years) and a statement of the group leader of the department where the scientific work submitted for the Aspirin® Award competition was generated which describes the background and rationale of the research, confirms the independence of the scientific work and discloses the source of financial funding.

Applications should be mailed to the following address:

International Aspirin® Award
c/o Bayer AG
BG Consumer Care/EU-PDC/Medicine
Building C 151
D-51368 Leverkusen/Germany

Deadline for submission is April 30th, 1998 (postal mark!)



The American Association for Cancer Research Presents

Molecular Biology in Clinical Oncology: A Workshop Supported by a Generous Grant from the National Cancer Institute

An intensive, one-week summer workshop on molecular biology designed for clinical oncologists in training or in their early academic careers.

July 3-9, 1998
Given Biomedical Institute
Aspen, Colorado

ORGANIZERS

MICHAEL B. KASTAN
The Johns Hopkins
Oncology Center
Baltimore, MD

L. MICHAEL GLODÉ
University of Colorado
School of Medicine
Denver, CO

JENNIFER A. PIETENPOL
Vanderbilt University
School of Medicine
Nashville, TN

- Lectures by leading experts on molecular biology concepts and the latest developments in molecular oncology. Topics include gene therapy, oncogenes and growth factors, tumor suppressor genes, molecular genetics, metastasis genes, and drug design.
- Small group laboratory sessions to demonstrate the important experimental techniques utilized in molecular biology.
- A workshop syllabus containing relevant published papers, references to key articles in the literature, and details on important laboratory procedures.
- Financial support for participants who are physicians in training or oncology fellows.

Faculty

Lectures

KATHLEEN R. CHO/ Baltimore, MD

CHI VAN DANG/ Baltimore, MD

ERIC R. FEARON/ Ann Arbor, MI

TYLER JACKS/ Cambridge, MA

MICHAEL B. KASTAN/ Baltimore, MD

ROBERT S. KERBEL/ Toronto, ON, Canada

MARC E. LIPPMAN/ Washington, DC

EDISON T. LIU/ Bethesda, MD

A. THOMAS LOOK/ Memphis, TN

SANFORD MARKOWITZ/ Cleveland, OH

HAROLD L. MOSES/ Nashville, TN

GARY J. NABEL/ Ann Arbor, MI

PERRY D. NISEN/ Abbott Park, IL

ELAINE OSTRANDER/ Seattle, WA

DREW PARDOLL/ Baltimore, MD

JENNIFER A. PIETENPOL/ Nashville, TN

FRANK J. RAUSCHER, III/ Philadelphia, PA

NADIA ROSENTHAL/ Charlestown, MA

ERIC J. STANBRIDGE/ Irvine, CA

Laboratory Rotations

MARK S. BOGUSKI/ Bethesda, MD. "Computer Searching in Molecular Biology."

LAB DIRECTOR TO BE ANNOUNCED/ "Specialized Techniques in PCR."

JAMES P. HOEFFLER/ San Diego, CA. "Protein Expression."

ROBERT A. SCLAFANI/ Denver, CO. "Transcript Array Analysis."

LAB DIRECTOR TO BE ANNOUNCED "Inducible Gene Expression Systems."

Application Deadline March 30, 1998

For further information, contact

American Association for Cancer Research

Public Ledger Building, Suite 826


150 S. Independence Mall West

Philadelphia, PA 19106-3483

Telephone: (215) 440-9300 • FAX: (215) 440-9313

Email: meetings@aacr.org





Portrayed on the cover are the recipients of the annual awards of the American Association for Cancer Research (AACR) for 1998. The awardees will present lectures during the 89th Annual Meeting, March 28–April 1, 1998, New Orleans, LA, at the Morial Convention Center.

The G. H. A. Clowes Memorial Award is presented annually for outstanding accomplishments in basic cancer research. Supported by Eli Lilly and Company, this award is in memory of Dr. Clowes who was a founding member of the AACR and Research Director at Eli Lilly. The 1998 Clowes Award is presented to Arnold J. Levine,* Ph.D. (*bottom row, second from left*), Harry C. Weiss Professor in the Life Sciences in the Department of Molecular Biology at Princeton University. Dr. Levine is being honored for his discovery in 1979 of the *p53* gene (over 50% of all human cancers have mutations in both alleles of this gene), and for his subsequent series of outstanding experiments that have increased our knowledge of its mechanisms and functions. Among the highlights of Dr. Levine's work on the *p53* gene are the discoveries that only the mutant form of the *p53* gene is associated with cell transformation and that the normal form of *p53* can act as a tumor suppressor gene. In addition to his *p53* work, Dr. Levine has made valuable contributions to our knowledge of adenovirus and SV40 biology in addition to the Epstein-Barr virus and the human papilloma virus. Dr. Levine's award lecture is entitled, "The Regulation and Function of the *p53* Tumor Suppressor Protein."

Awarded for outstanding research leading to improved clinical care in the field of cancer, the 1998 Richard and Hinda Rosenthal Foundation Award is presented to Lee M. Nadler,** M.D. (*bottom row, far left*), Chair of the Department of Adult

Oncology at the Dana-Farber Cancer Institute, Chief of the Division of Medical Oncology at Brigham and Women's Hospital, and Professor of Medicine at Harvard Medical School in Boston. Dr. Nadler is being honored for his multiple major contributions to the fields of lymphoma biology and therapy, in addition to tumor immunology. His studies on cell surface proteins laid the groundwork for a more precise understanding of B-cell malignancies and their normal lymphoid counterparts. He pioneered studies regarding the role of high-dose therapy in the indolent B-cell lymphomas. His recent work on tumor immunity has the potential to transform our approaches to the treatment of both lymphoid and epithelial tumors. Dr. Nadler's award lecture is entitled, "From the Human B-Cell Surface to the Bedside."

The Cornelius P. Rhoads Memorial Award recognizes outstanding contributions to cancer research by a scientist under the age of 41. It honors Cornelius P. Rhoads, a founder and first director of the Sloan-Kettering Institute for Cancer Research. The 19th Rhoads Award recipient is Michael C. Dean, Ph.D. (*top row, center*), Chief of the Human Genetics Section at the Laboratory of Genomic Diversity at the National Cancer Institute at the Frederick Cancer Research and Development Center in Frederick, MD. Dr. Dean is being honored for multiple contributions to cancer research in a variety of fields. Examples of his varied and outstanding contributions include research on the *MET* oncogene and its link to the cystic fibrosis gene which led to the cloning of the latter gene and which showed that *MET* is mutant in the germline of hereditary papillary renal carcinoma; participation in the cloning of the *VHL* gene and the discovery of germline mutations in *VHL* patients; mapping of the *CCR5* gene, a receptor for HIV, and identification of a variant that leads to resistance to HIV infection in homozygous persons and to prolonged survival in those heterozygous for the mutation; contributions to cloning the nevoid basal cell carcinoma syndrome gene and demonstrating that it is the human homologue of the *drosophila* segment polarity gene, *patched*; and characterization of more than 20 new human ATP-binding cassette genes, work that has increased our understanding of P-glycoprotein and multidrug resistance-related protein. Dr. Dean's award lecture is entitled, "Cancer as a Complex Development Disorder."

Established by Warner-Lambert, the Bruce F. Cain Memorial Award is presented for outstanding preclinical investigations leading to the improved care of cancer patients. This year's awardee is Bruce A. Chabner, M.D. (*top row, left*), Professor of Medicine at Harvard Medical School, Director of the Clinical Cancer Center, Chief of the Division of Medical Hematology and Oncology, Physician at the Massachusetts General Hospital, and Chief Medical Officer of Dana-Farber/Partners Cancer Care in Boston. The award recognizes Dr. Chabner's outstanding work performed over more than two decades on the basic and clinical pharmacology of anticancer agents, notably the antifolates. This work has made a significant contribution to defining the use of these drugs in various cancers and has helped to lay the foundation for the utilization

* Photograph by Robert P. Matthews.

** Photograph by David Witbeck.

of leucovorin reversal of methotrexate toxicity. He is also being recognized for his application of the pharmacological properties of drugs to the development of new drugs and to the design of more effective combination chemotherapy, leading to some of the most effective and curative therapeutic regimens for non-Hodgkin's lymphoma. More recently, he has made noteworthy contributions to the elucidation of mechanisms of clinical drug resistance. Dr. Chabner's award lecture is entitled, "Translational Research: Walking the Bridge between Idea and Cure."

Research accomplishments in cancer epidemiology, biomarkers, and prevention is the focus of the 7th American Cancer Society Award presented to Ernst L. Wynder, M.D. (*bottom row, far right*), President and Medical Director of the American Health Foundation, Consultant at Memorial Sloan-Kettering Cancer Center and Memorial Hospital in New York, NY, Clinical Professor of Community and Preventive Medicine at the New York Medical College in Valhalla, NY, and a Consultant in the Department of Medicine at Memorial Sloan-Kettering Cancer Center. Dr. Wynder is being recognized as having been the first scientist in the United States to identify the relationship between cigarette smoking and lung cancer in a large-scale epidemiological study published in 1950. He fought hard thereafter to gain acceptance for the validity of this relationship by providing further experimental and epidemiological evidence, becoming the first to demonstrate that the application of tobacco smoke condensate to mouse skin caused tumors. Later, he performed extensive studies which demonstrated the link between smoking and carcinomas other than lung cancer and was one of the first to recognize the importance of dietary factors in the etiology of major cancers. Dr. Wynder's lecture is entitled, "The Past, Present, and Future of the Prevention of Lung Cancer."

The Joseph H. Burchenal AACR Clinical Research Award honors an investigator for significant contributions to clinical care in the field of cancer. Sponsored by Bristol-Myers Squibb Oncology, this award was named after AACR Honorary Member and Past President Joseph H. Burchenal, M.D., who conducted outstanding research in the field of cancer chemotherapy during his long and distinguished career at Memorial Sloan-Kettering Cancer Institute. The third Burchenal Award will be presented to Bernard Fisher, M.D. (*top row, right*), Director of Research of the Division of Human Oncology at the Allegheny University of the Health Sciences, Distinguished Service Professor at the University of Pittsburgh, and Scientific Director of the National Surgical Adjuvant Breast and Bowel

Project (NSABP). Dr. Fisher is being honored for his many contributions to clinical investigations in cancer. His early work on tumor metastasis paved the way for later hypotheses about the spread of the disease. In addition, his systematic clinical trials changed the way physicians manage local-regional and systemic disease in patients with carcinoma of the breast. Those changes improved both survival rates and quality of life for a countless number of women. Of particular importance has been his demonstration of the effectiveness of breast conservation for both invasive and noninvasive breast cancer, adjuvant chemotherapy and hormonal therapy (tamoxifen), and his role in initiating the first women's health trial to evaluate the use of tamoxifen for preventing breast cancer in women with increased risk for the disease. His award lecture is entitled, "The Biology and Therapy of Breast Cancer: Reflections from Several Perspectives."

The AACR-Pezcoller International Award for Cancer Research is a new award, given biennially. Over the past decade, the Pezcoller Foundation has given a major award for outstanding contributions to cancer and cancer-related biomedical science, and this award is now given in collaboration with the AACR to recognize a scientist who has made a major scientific discovery in the field of cancer research. The First AACR-Pezcoller International Award recipient is Anthony J. Pawson, Ph.D. (*bottom row, second from right*), Senior Scientist and Head of the Programme in Molecular Biology and Cancer at the Samuel Lunenfeld Research Institute, Apotex Chair in Oncology at Mount Sinai Hospital, Professor at the University of Toronto, and Terry Fox Cancer Research Scientist at the National Cancer Institute of Canada in Toronto, Ontario. Dr. Pawson is being recognized for revolutionizing our understanding of signal transduction and the molecular mechanisms by which cells respond to external cues. He is known for his discovery of SH2 domains, demonstrating their role in mediating protein-protein interactions. Dr. Pawson's research, particularly his pioneering work on protein modules that control intracellular signaling downstream of tyrosine kinases, has the broadest implications for understanding both the normal process of cell signaling and the breakdowns in signaling that underlie cancer. In addition, his research has suggested that blocking signaling pathways may be a promising new strategy for the design of novel cancer chemotherapeutic agents. His award lecture is entitled, "SH2 Domains and Modular Proteins Control Signal Transduction Pathways."

We are indebted to the awardees and the award selection committees for their assistance in preparing this legend.